| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Copper (NY)
Test Code13615
CPT Codes
82525 <br><strong> This test is for New York patient testing only. For non-New York patient testing use test code 363.</strong>
Preferred Specimen
2 mL plasma collected in an EDTA (royal blue-top) tube or heparin (royal blue-top) tube
Minimum Volume
0.7 mL
Other Acceptable Specimens
Serum collected in: No additive (royal blue-top) tube
Instructions
Separate serum or plasma from cells within two hours. Transfer separated plasma/serum to a plastic acid-washed or metal-free vial.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 5 days
Refrigerated: 10 days
Frozen: 30 days
Refrigerated: 10 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Plasma/serum not separated from cells within 2 hours • Samples submitted in non-trace element or non-acid washed container
Methodology
Inductively Coupled Plasma/Mass Spectrometry (ICP/MS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Sun, Wed, Fri; Report available: 1-4 days
Clinical Significance
Copper is an essential element that is a cofactor of many enzymes. Copper metabolism is disturbed in Wilson's disease, Menkes disease, primary biliary cirrhosis, and Indian childhood cirrhosis. Copper concentrations increase in acute phase reactions and during the third trimester of pregnancy. Copper concentrations are decreased with nephrosis, malabsorption, and malnutrition. Copper concentrations are also useful to monitor patients, especially preterm newborns, on nutritional supplementation. Results of copper are often interpreted together with ceruloplasmin.
